FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094205168> ?p ?o ?g. }

• W3094205168 endingPage "915" @default.
• W3094205168 startingPage "903" @default.
• W3094205168 abstract "Purpose To evaluate the effectiveness and explore the therapeutic mechanisms of platelet-rich plasma (PRP) combined with hyaluronic acid (HA) as a treatment for knee osteoarthritis (KOA). Methods In total, 122 knees were randomly divided into HA (34 knees), PRP (40 knees), and PRP+HA (48 knees) groups. Platelet densities in whole blood and PRP were examined using Wright–Giemsa staining. Visual analogue scale, Lequesne, Western Ontario and McMaster Universities Osteoarthritis Index, Lysholm scores, and postoperative complications were evaluated. High-frequency color Doppler imaging was used to observe the synovium and cartilage. Enzyme-linked immunosorbent assays were used to quantify interleukin-1β, tumor necrosis factor-α, matrix metalloproteinase-3, and tissue inhibitor of metalloproteinase-1 levels in synovial fluid. Results The platelet density in PRP was 5.13-times that in whole blood (P = .002). At 24 months, pain and function scores in the PRP+HA group were better than those in the HA-alone and PRP-alone groups (Ppain = .000; Pfunction = .000). At 6 and 12 months, synovial hyperplasia in the PRP and PRP+HA groups was improved (P < .05). After 6 and 12 months, the synovial peak systolic velocity, synovial end-diastolic velocity, systolic/diastolic ratio, and resistance index were improved in the PRP+HA group (P < .05). Complications were greatest in the PRP group (P = .008). After 6 and 12 months, interleukin-1β, tumor necrosis factor-α, matrix metalloproteinase-3, and tissue inhibitor of metalloproteinase-1 in the PRP and PRP+HA groups decreased (P < .05), with more apparent inhibition in the PRP+HA group (P < .05). Conclusions PRP combined with HA is more effective than PRP or HA alone at inhibiting synovial inflammation and can effectively improve pain and function and reduce adverse reactions. Its mechanism involves changes in the synovium and cytokine content. Level of Evidence Level II, Prospective cohort study. To evaluate the effectiveness and explore the therapeutic mechanisms of platelet-rich plasma (PRP) combined with hyaluronic acid (HA) as a treatment for knee osteoarthritis (KOA). In total, 122 knees were randomly divided into HA (34 knees), PRP (40 knees), and PRP+HA (48 knees) groups. Platelet densities in whole blood and PRP were examined using Wright–Giemsa staining. Visual analogue scale, Lequesne, Western Ontario and McMaster Universities Osteoarthritis Index, Lysholm scores, and postoperative complications were evaluated. High-frequency color Doppler imaging was used to observe the synovium and cartilage. Enzyme-linked immunosorbent assays were used to quantify interleukin-1β, tumor necrosis factor-α, matrix metalloproteinase-3, and tissue inhibitor of metalloproteinase-1 levels in synovial fluid. The platelet density in PRP was 5.13-times that in whole blood (P = .002). At 24 months, pain and function scores in the PRP+HA group were better than those in the HA-alone and PRP-alone groups (Ppain = .000; Pfunction = .000). At 6 and 12 months, synovial hyperplasia in the PRP and PRP+HA groups was improved (P < .05). After 6 and 12 months, the synovial peak systolic velocity, synovial end-diastolic velocity, systolic/diastolic ratio, and resistance index were improved in the PRP+HA group (P < .05). Complications were greatest in the PRP group (P = .008). After 6 and 12 months, interleukin-1β, tumor necrosis factor-α, matrix metalloproteinase-3, and tissue inhibitor of metalloproteinase-1 in the PRP and PRP+HA groups decreased (P < .05), with more apparent inhibition in the PRP+HA group (P < .05). PRP combined with HA is more effective than PRP or HA alone at inhibiting synovial inflammation and can effectively improve pain and function and reduce adverse reactions. Its mechanism involves changes in the synovium and cytokine content." @default.
• W3094205168 created "2020-10-29" @default.
• W3094205168 creator A5012384237 @default.
• W3094205168 creator A5022578803 @default.
• W3094205168 creator A5040880045 @default.
• W3094205168 creator A5054388396 @default.
• W3094205168 creator A5068331812 @default.
• W3094205168 creator A5091240258 @default.
• W3094205168 date "2021-03-01" @default.
• W3094205168 modified "2023-10-13" @default.
• W3094205168 title "Intra-Articular Platelet-Rich Plasma Combined With Hyaluronic Acid Injection for Knee Osteoarthritis Is Superior to Platelet-Rich Plasma or Hyaluronic Acid Alone in Inhibiting Inflammation and Improving Pain and Function" @default.
• W3094205168 cites W1031259716 @default.
• W3094205168 cites W1728787893 @default.
• W3094205168 cites W1773219259 @default.
• W3094205168 cites W1966570170 @default.
• W3094205168 cites W1972083293 @default.
• W3094205168 cites W1983047610 @default.
• W3094205168 cites W2002731655 @default.
• W3094205168 cites W2006050540 @default.
• W3094205168 cites W2013758722 @default.
• W3094205168 cites W2014753761 @default.
• W3094205168 cites W2016107886 @default.
• W3094205168 cites W2024745401 @default.
• W3094205168 cites W2034516700 @default.
• W3094205168 cites W2035394856 @default.
• W3094205168 cites W2035765664 @default.
• W3094205168 cites W2044070981 @default.
• W3094205168 cites W2049593971 @default.
• W3094205168 cites W2056268132 @default.
• W3094205168 cites W2064413596 @default.
• W3094205168 cites W2080939900 @default.
• W3094205168 cites W2082954333 @default.
• W3094205168 cites W2103946264 @default.
• W3094205168 cites W2133094741 @default.
• W3094205168 cites W2137934350 @default.
• W3094205168 cites W2138012333 @default.
• W3094205168 cites W2139382287 @default.
• W3094205168 cites W2148990310 @default.
• W3094205168 cites W2166411844 @default.
• W3094205168 cites W2170794587 @default.
• W3094205168 cites W2215687845 @default.
• W3094205168 cites W2293561363 @default.
• W3094205168 cites W2296048819 @default.
• W3094205168 cites W2296531092 @default.
• W3094205168 cites W2327421967 @default.
• W3094205168 cites W2343734780 @default.
• W3094205168 cites W2401996906 @default.
• W3094205168 cites W2512835940 @default.
• W3094205168 cites W2531097686 @default.
• W3094205168 cites W2564076023 @default.
• W3094205168 cites W2571855531 @default.
• W3094205168 cites W2584503597 @default.
• W3094205168 cites W2620667888 @default.
• W3094205168 cites W2728814030 @default.
• W3094205168 cites W2766075424 @default.
• W3094205168 cites W2777262133 @default.
• W3094205168 cites W2784772121 @default.
• W3094205168 cites W2799714810 @default.
• W3094205168 cites W2807477579 @default.
• W3094205168 cites W2887946487 @default.
• W3094205168 cites W2888787767 @default.
• W3094205168 cites W2890671494 @default.
• W3094205168 cites W2907286282 @default.
• W3094205168 cites W2990124994 @default.
• W3094205168 cites W2999857563 @default.
• W3094205168 cites W3010464793 @default.
• W3094205168 cites W3016097108 @default.
• W3094205168 doi "https://doi.org/10.1016/j.arthro.2020.10.013" @default.
• W3094205168 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33091549" @default.
• W3094205168 hasPublicationYear "2021" @default.
• W3094205168 type Work @default.
• W3094205168 sameAs 3094205168 @default.
• W3094205168 citedByCount "40" @default.
• W3094205168 countsByYear W30942051682021 @default.
• W3094205168 countsByYear W30942051682022 @default.
• W3094205168 countsByYear W30942051682023 @default.
• W3094205168 crossrefType "journal-article" @default.
• W3094205168 hasAuthorship W3094205168A5012384237 @default.
• W3094205168 hasAuthorship W3094205168A5022578803 @default.
• W3094205168 hasAuthorship W3094205168A5040880045 @default.
• W3094205168 hasAuthorship W3094205168A5054388396 @default.
• W3094205168 hasAuthorship W3094205168A5068331812 @default.
• W3094205168 hasAuthorship W3094205168A5091240258 @default.
• W3094205168 hasConcept C105702510 @default.
• W3094205168 hasConcept C126322002 @default.
• W3094205168 hasConcept C142724271 @default.
• W3094205168 hasConcept C204787440 @default.
• W3094205168 hasConcept C2776164576 @default.
• W3094205168 hasConcept C2777077863 @default.
• W3094205168 hasConcept C2777529286 @default.
• W3094205168 hasConcept C2779244835 @default.
• W3094205168 hasConcept C2780076745 @default.
• W3094205168 hasConcept C71924100 @default.
• W3094205168 hasConcept C89560881 @default.
• W3094205168 hasConcept C90924648 @default.
• W3094205168 hasConceptScore W3094205168C105702510 @default.
• W3094205168 hasConceptScore W3094205168C126322002 @default.
• W3094205168 hasConceptScore W3094205168C142724271 @default.

• next